Patents by Inventor Naoko Namiki

Naoko Namiki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same
    Patent number: 11739143
    Abstract: The invention provides methods for using and compositions of humanized antibodies that bind tau protein that is phosphorylated at the serine at position 413.
    Type: Grant
    Filed: December 15, 2020
    Date of Patent: August 29, 2023
    Assignees: TEIJIN PHARMA LIMITED, MERCK SHARP & DOHME LLC
    Inventors: Hiroshi Eguchi, Takashi Murakami, Naoko Namiki, Akira Tanokura, Jeanne E. Baker, Sophie Parmentier Batteur, Angela Marie Jablonski, Daniel Stephen Malashock, Carl Mieczkowski, Gopalan (Raghu) Raghunathan
  • ANTI-IGF-I RECEPTOR ANTIBODY
    Publication number: 20230192868
    Abstract: The present invention provides an anti-IGF-I receptor antibody that binds specifically to an IGF-I receptor of a vertebrate and has the proliferation-inducing activity of a vertebrate-derived cell, or a fragment thereof, or derivatives of these.
    Type: Application
    Filed: March 2, 2023
    Publication date: June 22, 2023
    Applicant: Teijin Pharma Limited
    Inventors: Hiroshi EGUCHI, Akira Tanokura, Kenichiro Takagi, Hirotsugu KATO, Satoshi YAMAMURA, Naoko NAMIKI
  • Anti-IGF-I receptor antibodies, encoding nucleic acid molecules and methods of using said antibodies
    Patent number: 11629194
    Abstract: The present invention provides an anti-IGF-I receptor antibody that binds specifically to an IGF-I receptor of a vertebrate and has the proliferation-inducing activity of a vertebrate-derived cell, or a fragment thereof, or derivatives of these.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: April 18, 2023
    Assignee: Teijin Pharma Limited
    Inventors: Hiroshi Eguchi, Akira Tanokura, Kenichiro Takagi, Hirotsugu Kato, Satoshi Yamamura, Naoko Namiki
  • ANTI-IGF-I RECEPTOR HUMANIZED ANTIBODY
    Publication number: 20220033485
    Abstract: Provided is a humanized antibody that, through IGF-I receptor, increases muscle mass but does not lower the blood glucose level. This humanized antibody: is an anti-IGF-I receptor humanized antibody, a fragment thereof, or a derivative thereof; has a specific amino acid sequence such as SEQ ID NOs: 1 to 6 serving as a CDR sequence; and specifically binds to IGF-I receptor extracellular domain.
    Type: Application
    Filed: December 2, 2019
    Publication date: February 3, 2022
    Applicant: Teijin Pharma Limited
    Inventors: Akira TANOKURA, Hirotsugu KATO, Hiroshi EGUCHI, Kenichiro TAKAGI, Satoshi YAMAMURA, Naoko NAMIKI, Daisuke ISHIKAWA, Hirofumi HIGUCHI, Tomoyo TAKEO, Masayo OHORI
  • HUMANIZED ANTIBODY FOR TREATING OR PREVENTING COGNITIVE DISORDERS, PROCESS FOR PRODUCING THE SAME, AND AGENT FOR TREATING OR PREVENTING COGNITIVE DISORDERS USING THE SAME
    Publication number: 20210380677
    Abstract: The invention provides methods for using and compositions of humanized antibodies that bind tau protein that is phosphorylated at the serine at position 413.
    Type: Application
    Filed: December 15, 2020
    Publication date: December 9, 2021
    Applicants: TEIJIN PHARMA LIMITED, MERCK SHARP & DOHME CORP.
    Inventors: Hiroshi Eguchi, Takashi Murakami, Naoko Namiki, Akira Tanokura, Jeanne E. Baker, Sophie Parmentier Batteur, Angela Marie Jablonski, Daniel Stephen Malashock, Carl Mieczkowski, Gopalan (Raghu) Raghunathan
  • Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same
    Patent number: 10894829
    Abstract: The invention provides methods for using and compositions of humanized antibodies that bind tau protein that is phosphorylated at the serine at position 413.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: January 19, 2021
    Assignees: TEIJIN PHARMA LIMITED, MERCK SHARP & DOHME CORP.
    Inventors: Hiroshi Eguchi, Takashi Murakami, Naoko Namiki, Akira Tanokura, Jeanne E. Baker, Sophie Parmentier Batteur, Angela Marie Jablonski, Daniel Stephen Malashock, Carl Mieczkowski, Gopalan (Raghu) Raghunathan
  • HUMANIZED ANTIBODY FOR TREATING OR PREVENTING COGNITIVE DISORDERS, PROCESS FOR PRODUCING THE SAME, AND AGENT FOR TREATING OR PREVENTING COGNITIVE DISORDERS USING THE SAME
    Publication number: 20200223916
    Abstract: The invention provides methods for using and compositions of humanized antibodies that bind tau protein that is phosphorylated at the serine at position 413.
    Type: Application
    Filed: January 17, 2020
    Publication date: July 16, 2020
    Applicants: TEIJIN PHARMA LIMITED, MERCK SHARP & DOHME CORP.
    Inventors: Hiroshi Eguchi, Takashi Murakami, Naoko Namiki, Akira Tanokura, Jeanne E. Baker, Sophie Parmentier Batteur, Angela Marie Jablonski, Daniel Stephen Malashock, Carl Mieczkowski, Gopalan (Raghu) Raghunathan
  • ANTI-IGF-I RECEPTOR ANTIBODY
    Publication number: 20200115460
    Abstract: The present invention provides an anti-IGF-I receptor antibody that binds specifically to an IGF-I receptor of a vertebrate and has the proliferation-inducing activity of a vertebrate-derived cell, or a fragment thereof, or derivatives of these.
    Type: Application
    Filed: May 29, 2018
    Publication date: April 16, 2020
    Applicant: TEIJIN PHARMA LIMITED
    Inventors: Hiroshi EGUCHI, Akira TANOKURA, Kenichiro TAKAGI, Hirotsugu KATO, Satoshi YAMAMURA, Naoko NAMIKI
  • Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same
    Patent number: 10556950
    Abstract: The invention provides methods for using and compositions of humanized antibodies that bind tau protein that is phosphorylated at the serine at position 413.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: February 11, 2020
    Assignees: TEIJIN PHARMA LIMITED, MERCK SHARP & DOHME CORP.
    Inventors: Hiroshi Eguchi, Takashi Murakami, Naoko Namiki, Akira Tanokura, Jeanne E. Baker, Sophie Parmentier Batteur, Angela Marie Jablonski, Daniel Stephen Malashock, Carl Mieczkowski, Gopalan (Raghu) Raghunathan
  • HUMANIZED ANTIBODY FOR TREATING OR PREVENTING COGNITIVE DISORDERS, PROCESS FOR PRODUCING THE SAME, AND AGENT FOR TREATING OR PREVENTING COGNITIVE DISORDERS USING THE SAME
    Publication number: 20180346564
    Abstract: The invention provides methods for using and compositions of humanized antibodies that bind tau protein that is phosphorylated at the serine at position 413.
    Type: Application
    Filed: February 27, 2018
    Publication date: December 6, 2018
    Inventors: Hiroshi Eguchi, Takashi Murakami, Naoko Namiki, Akira Tanokura, Jeanne E. Baker, Sophie Parmentier Batteur, Angela Marie Jablonski, Daniel Stephen Malashock, Carl Mieczkowski, Gopalan (Raghu) Raghunathan